Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Eur Neuropsychopharmacol. 2015 May 21;25(10):1650–1660. doi: 10.1016/j.euroneuro.2015.05.006

Figure 4. pSP4/SP4 ratio in the cerebellum associates with negative symptom severity in schizophrenia.

Figure 4

Protein extracts from cerebellum of subjects with schizophrenia (n=15) were analyzed by immunoblotting for pSP4 and GAPDH and pSP4/SP4 ratio was computed by referring pSP4 to previously reported SP4 protein levels from the same samples (Pinacho et al., 2013). (A) Images show representative pSP4, SP4 and GAPDH immunoblots of four representative schizophrenia subjects and their score for negative symptoms measured by the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Schizophrenia scale (CGI-SCH). Full-length blots are shown in Figure S3. The graphs represent pSP4/SP4 ratio and negative symptom severity measured with the PANSS (B) and the CGI-SCH (C) scales. Data were adjusted to a linear regression. Statistical analysis was performed using Spearman correlation; Spearman's r is indicated for each analysis (*p<0.05; #p=0.0679).